SCHEMBL4282157

SCHEMBL4282157

O=C1NCCN1CCCC(c1ccc(F)cc1)c1ccc(F)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.55
POLB P06746 2/20 0.55
HTR2A P28223 6/20 0.48
ADRA1A P35348 6/20 0.48
HRH1 P35367 6/20 0.48
DRD3 P35462 6/20 0.48
OPRK1 P41145 6/20 0.48
SLC6A3 Q01959 6/20 0.48
OPRM1 P35372 5/20 0.48
HTR6 P50406 5/20 0.48
CACNA1C Q13936 5/20 0.48
CYP3A4 P08684 5/20 0.48
CYP2D6 P10635 5/20 0.48
ADORA3 P0DMS8 5/20 0.48
OPRD1 P41143 5/20 0.48
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
HTR2C P28335 4/20 0.48
DRD2 P14416 4/20 0.48
CYP1A2 P05177 4/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14244100 0.96 ALDH1A1 (0.54) ALDH1A1POLBHTR2AADRA1AHRH1
SCHEMBL13780826 0.87 RET (0.56) ALDH1A1POLBHTR2AADRA1AHRH1
SCHEMBL13504722 0.77 HTR2A (0.59) ALDH1A1HTR2AADRA1AHRH1DRD3
SCHEMBL4290152 0.77 CYP3A4 (0.48) ALDH1A1HTR2AADRA1AHRH1DRD3
SCHEMBL4285624 0.76 RAB9A (0.44) ALDH1A1POLBHTR2AADRA1AHRH1
SCHEMBL14641553 0.75 CYP3A4 (0.46) ALDH1A1HTR2AADRA1AHRH1DRD3
SCHEMBL7295696 0.75 SCN5A (0.58) ALDH1A1HTR2AADRA1AHRH1DRD3
SCHEMBL2268114 0.75 SIGMAR1 (0.58) ALDH1A1HTR2AADRA1AHRH1DRD3
SCHEMBL10556025 0.75 SCN5A (0.58) ALDH1A1HTR2AADRA1AHRH1DRD3
SCHEMBL11338768 0.75 SIGMAR1 (0.58) ALDH1A1HTR2AADRA1AHRH1DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8354434-B2 Cyclourea compounds as calcium channel blockers PURDUE PHARMA L.P. (US) 2013-01-15 US claimed
US-20090176838-A1 Cyclourea Compounds as Calcium Channel Blockers PURDUE PHARMA L.P. (US) 2009-07-09 US claimed
EP-1987009-A1 CYCLOUREA COMPOUNDS AS CALCIUM CHANNEL BLOCKERS EURO-CELTIQUE S.A. (LU) 2008-11-05 EP claimed
WO-2007085357-A1 CYCLOUREA COMPOUNDS AS CALCIUM CHANNEL BLOCKERS EURO-CELTIQUE S.A. (LU) 2007-08-02 WO claimed
US-8354434-B2 Cyclourea compounds as calcium channel blockers PURDUE PHARMA L.P. (US) 2013-01-15 US disclosed
US-8354434-B2 Cyclourea compounds as calcium channel blockers PURDUE PHARMA L.P. (US) 2013-01-15 US disclosed
US-8354434-B2 Cyclourea compounds as calcium channel blockers PURDUE PHARMA L.P. (US) 2013-01-15 US disclosed
US-20120322830-A1 Cyclourea Compounds as Calcium Channel Blockers PURDUE PHARMA L.P. (US) 2012-12-20 US disclosed
US-20120322830-A1 Cyclourea Compounds as Calcium Channel Blockers PURDUE PHARMA L.P. (US) 2012-12-20 US disclosed
US-20120322830-A1 Cyclourea Compounds as Calcium Channel Blockers PURDUE PHARMA L.P. (US) 2012-12-20 US disclosed
US-20090176838-A1 Cyclourea Compounds as Calcium Channel Blockers PURDUE PHARMA L.P. (US) 2009-07-09 US disclosed
US-20090176838-A1 Cyclourea Compounds as Calcium Channel Blockers PURDUE PHARMA L.P. (US) 2009-07-09 US disclosed
US-20090176838-A1 Cyclourea Compounds as Calcium Channel Blockers PURDUE PHARMA L.P. (US) 2009-07-09 US disclosed
EP-1987009-A1 CYCLOUREA COMPOUNDS AS CALCIUM CHANNEL BLOCKERS EURO-CELTIQUE S.A. (LU) 2008-11-05 EP disclosed
WO-2007085357-A1 CYCLOUREA COMPOUNDS AS CALCIUM CHANNEL BLOCKERS EURO-CELTIQUE S.A. (LU) 2007-08-02 WO disclosed
WO-2007085357-A1 CYCLOUREA COMPOUNDS AS CALCIUM CHANNEL BLOCKERS EURO-CELTIQUE S.A. (LU) 2007-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120322830-A1 Cyclourea Compounds as Calcium Channel Blockers CACNA1E, CACNA1B, CACNA1D ALDH1A1 4063/4885POLB 4003/4885HTR2A 2172/4885
US-20090176838-A1 Cyclourea Compounds as Calcium Channel Blockers CACNA1E, CACNA1B, CACNA1D ALDH1A1 4063/4885POLB 4003/4885HTR2A 2172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.